Following treatment with both agents, histological analysis of severely ischemic grafts demonstrated similar lymphocyte infiltration and vasculopathy compared to control non-ischemic grafts (Fig. 6B), indicating that anti-IL-6 synergized with sCTLA4Ig and overcame the effect of severe ischemia on alloimmune activation to produce long term graft survival. The gene discussed is IL6; the disease is vascular disorder.